Intima Bioscience

A clinical trial to assess the safety and efficacy of genetically-engineered, neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune Checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of Gastro-Intestinal Cancer.

Please watch the video below to learn more about our proprietary Checkpoint Cell Therapy, combining two cutting edge therapies for solid tumor cancer in a single clinical trial. A next generation checkpoint inhibitor, CISH with genetically engineered T cell therapy for solid tumors.

Intima Bioscience is conducting a clinical trial initially at the University of Minnesota Masonic Cancer Center with its Molecular and Cell Therapy (MCT) GMP gene and cell therapy manufacturing facility.

A clinical stage gene and cell therapy company focused on curative intent in solid tumor cancer